KALA KALA BIO, Inc.
Healthcare$2.17-10.70%ClosedMarket Cap: $47.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.84
P/S
0.00
EV/EBITDA
-1.81
DCF Value
$0.81
FCF Yield
-48.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-1335.6%
ROA
-159.6%
ROIC
-281.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-1.8M | $-1.6M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-10.2M | $686.0K | $— | — |
| FY null | $0.00 | NaN% | $-39.2M | $-27.0M | $— | — |
| Q3 null | $0.00 | NaN% | $-7.2M | $-7.6M | $— | — |
| Q2 null | $0.00 | NaN% | $-11.0M | $-11.2M | $— | — |
| Q1 null | $0.00 | NaN% | $-10.7M | $-8.9M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-9.5M | $-8.2M | $— | — |
| FY null | $0.00 | -Infinity% | $-40.4M | $-38.5M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-9.6M | $-8.9M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-9.6M | $-9.6M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-11.8M | $-11.8M | $— | — |
| Q4 2023 | $70.0K | -100.0% | $-9.1M | $-8.6M | $-3.18 | — |